A single-dose tirzepatide vial and a once-weekly injection pen resting on a clean white pharmacy counter beside a tape measure under soft daylight.

Zepbound: Tirzepatide Built for Weight Loss — The Mounjaro Sibling, Explained

Updated 2026-06-15T00:00:00.000Z17 min read · 4,376 words

Zepbound is Eli Lilly's weight-loss brand of tirzepatide, the same dual-hormone molecule sold for type 2 diabetes as Mounjaro. If you have heard that one shot delivered bigger weight loss than Ozempic-style drugs in head-to-head testing, this is the brand behind that headline, and it ranks near the top of the options people weigh for weight loss. Zepbound is the product Lilly built specifically for obesity, and in late 2024 it also became the first drug ever approved to treat obstructive sleep apnea.

This is the brand and market hub. It answers the practical questions people search for: what Zepbound is, how much weight people lost in the SURMOUNT trials, how it stacks up against Wegovy, how it differs from its diabetes-branded sibling Mounjaro, the new sleep-apnea use, the dose strengths, and what it costs in 2026. For the underlying science of the molecule, including how the dual GIP and GLP-1 mechanism works and the full dosing and side-effect detail, we keep things short here and point you to the tirzepatide molecule guide. The goal is one clear map of the Zepbound brand.

Key Takeaways

  • Zepbound is the weight-loss brand of tirzepatide made by Eli Lilly, a once-weekly injection FDA-approved on November 8, 2023 for chronic weight management in adults with obesity or overweight plus a weight-related condition (Eli Lilly, 2023).
  • In the SURMOUNT-1 trial, adults lost up to about 20.9% of body weight at the 15 mg dose over 72 weeks, the result that anchored the obesity approval (Eli Lilly, 2022).
  • Head-to-head, Zepbound beat Wegovy: in the SURMOUNT-5 trial, tirzepatide produced about 20.2% weight loss versus 13.7% for semaglutide over 72 weeks (NEJM, 2025).
  • It is the first FDA-approved drug for obstructive sleep apnea, cleared in December 2024 for moderate-to-severe OSA in adults with obesity (Eli Lilly, 2024).
  • Zepbound and Mounjaro are the same drug (tirzepatide) under two brands: Zepbound for weight and sleep apnea, Mounjaro for type 2 diabetes (Eli Lilly, 2023).
  • Self-pay single-dose vials are cheaper than the pen: Lilly's LillyDirect lists 2.5 mg vials around $299 and 5 mg around $399 a month, while Medicare is barred by law from covering any drug for weight loss alone (Eli Lilly, LillyDirect, 2026; KFF, 2025).

How much weight do people lose on Zepbound?

In Zepbound's pivotal SURMOUNT-1 trial, adults with obesity or overweight lost roughly 16% to 21% of their body weight depending on dose over 72 weeks, with about 20.9% at the top 15 mg dose. Those numbers are the reason Zepbound exists as its own brand.

The SURMOUNT program tested tirzepatide specifically for weight, not blood sugar. In SURMOUNT-1, published in 2022, adults without diabetes lost an average of about 15% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg, against roughly 3% on placebo, over 72 weeks (Eli Lilly, 2022). The FDA approved Zepbound for chronic weight management on November 8, 2023, on the strength of SURMOUNT-1 and SURMOUNT-2 (Eli Lilly, 2023).

Two things matter for a reader. First, these figures come from a clinical trial alongside diet and exercise, not a guarantee for any individual. Second, the weight effect is dose-dependent, which is why people are titrated upward slowly. The trial also reported that a large majority of participants on the active doses lost at least 5% of their body weight, the threshold clinicians often use to call a weight-loss drug a success, and a meaningful share crossed the 15% and 20% marks (Eli Lilly, 2022).

It is worth separating the brand story from the headline number. The 20.9% figure is the average at the maximum dose in a controlled study; real-world results vary with the dose a person tolerates, how long they stay on it, and the lifestyle changes alongside it. That is the honest framing to carry into any comparison, including the one against Wegovy below. The mechanism behind the effect, the dual action on the GIP and GLP-1 receptors, lives on the tirzepatide molecule guide so this page can stay on the brand and market story.

Citation capsule. Zepbound (tirzepatide) is Eli Lilly's once-weekly injection FDA-approved on November 8, 2023 for chronic weight management; in the SURMOUNT-1 trial adults lost up to about 20.9% of body weight at the 15 mg dose over 72 weeks. Source: Eli Lilly, SURMOUNT-1 results and FDA approval announcements, 2022 to 2023.

Zepbound vs Wegovy: which loses more weight?

Zepbound and Wegovy are different molecules for the same goal, and in the first head-to-head trial Zepbound (tirzepatide) produced more weight loss than Wegovy (semaglutide). For most consumers shopping the weight-loss category, this is the comparison that matters.

The two drugs differ at the receptor level. Wegovy's semaglutide is a single GLP-1 receptor agonist, while Zepbound's tirzepatide acts on two gut-hormone receptors, GIP and GLP-1. In the SURMOUNT-5 trial, the first to test them head-to-head in adults with obesity but without diabetes, tirzepatide produced about 20.2% average weight loss versus 13.7% for semaglutide over 72 weeks, published in the New England Journal of Medicine in 2025 (NEJM, 2025). That is roughly half again as much weight lost.

Weight was not the only measure where the two diverged. In the same trial, tirzepatide produced a larger reduction in waist circumference than semaglutide, and the share of people reaching the deeper weight-loss milestones, such as losing a quarter of their body weight, was higher on tirzepatide (NEJM, 2025). Both drugs caused the familiar gut-related side effects, mostly nausea, diarrhea, and constipation, at broadly similar rates, so the gap in results was not simply a matter of one drug being harder to tolerate.

Bigger numbers do not automatically make Zepbound the right choice for everyone. Insurance coverage, side-effect tolerance, prior experience, and supply all factor in, and Wegovy carries its own approvals including cardiovascular risk reduction that Zepbound does not yet share for that exact endpoint. The trial average is a population result, not a personal prediction, and many people do well on either drug. The table below is the brand-level snapshot. The deep, dimension-by-dimension breakdown lives in the Zepbound vs Wegovy comparison and the Wegovy guide.

FeatureZepboundWegovy
MoleculeTirzepatide (dual GIP/GLP-1)Semaglutide (GLP-1)
MakerEli LillyNovo Nordisk
Avg weight loss (trial)~20.2% (SURMOUNT-5)~13.7% (SURMOUNT-5)
Form / frequencyWeekly injectionWeekly injection (and oral)
Approved usesWeight management; obstructive sleep apneaWeight management; cardiovascular risk
Dose strengths2.5 to 15 mgup to 2.4 mg
Zepbound vs Wegovy average weight loss (SURMOUNT-5)Zepbound beat Wegovy head-to-headAverage body-weight loss at 72 weeks. Source: SURMOUNT-5, NEJM 2025.0%10%20%~20.2%Zepboundtirzepatide~13.7%Wegovysemaglutide
In the first head-to-head obesity trial, tirzepatide produced roughly half again as much weight loss as semaglutide.

What is Zepbound approved to treat?

Zepbound is FDA-approved for two things: chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity. It is not approved for type 2 diabetes; that is what its sibling Mounjaro is for.

The weight-management approval came first, on November 8, 2023, for adults with a BMI of 30 or higher, or 27 or higher with a condition such as high blood pressure or high cholesterol, used alongside reduced calories and more activity (Eli Lilly, 2023). Then in December 2024, Zepbound became the first and only prescription medicine approved for moderate-to-severe obstructive sleep apnea in adults with obesity (Eli Lilly, 2024).

The sleep-apnea approval is a genuine differentiator, not a footnote. It rested on the SURMOUNT-OSA trial, which enrolled adults with obesity and moderate-to-severe OSA, both those using a PAP breathing machine and those not. Zepbound cut the number of breathing interruptions per hour far more than placebo and helped many participants improve enough that they no longer met the threshold for their OSA symptoms (Eli Lilly, 2024). In that trial, participants also lost a substantial share of body weight, which is the mechanism thought to drive the breathing improvement: less weight around the airway means fewer overnight obstructions.

For a reader, the practical importance is twofold. It is the first time a drug, rather than a device or surgery, has carried an FDA approval for OSA, and it gives Zepbound a medical indication separate from weight loss. That separation matters for coverage, because some plans treat a sleep-apnea diagnosis differently from obesity, a point we return to in the coverage section below.

A close-up of a single-dose tirzepatide vial and a syringe on a clean white surface under soft studio light, no text or logos.

Zepbound vs Mounjaro: same drug, two brands

Zepbound and Mounjaro are both tirzepatide made by Eli Lilly; the only real difference is the brand and the approved use, with Zepbound for weight and sleep apnea and Mounjaro for type 2 diabetes. If you have seen both names, you have seen one molecule wearing two labels.

This mirrors the Novo Nordisk playbook, where semaglutide is Ozempic for diabetes and Wegovy for weight. Lilly does the same with tirzepatide: Mounjaro is the diabetes brand, and Zepbound is the obesity and sleep-apnea brand. The active ingredient, the once-weekly schedule, and the dose ladder are the same drug. What changes is the indication on the label, the packaging, and how insurance treats each.

That split exists mostly for coverage and regulatory reasons. A plan that covers diabetes drugs may pay for Mounjaro but exclude Zepbound when the goal is weight loss, even though the vial holds the identical compound. It also means the two brands can have different list prices, different savings programs, and different supply situations at any given time, despite being the same drug. People sometimes ask whether they can simply use one brand for the other's purpose; in practice the prescription, the label, and the insurance approval all have to line up, which is why a clinician chooses the brand that fits your diagnosis. For the diabetes-side framing, see the Mounjaro guide; for the Novo Nordisk equivalent, the Ozempic guide. The molecule itself, shared by both brands, is in the tirzepatide molecule guide.

Our take: The two-brand setup confuses a lot of people who assume Zepbound and Mounjaro are competing drugs. They are not. If a clinic offers you "tirzepatide," it is the same molecule in either pen. The practical question is never which is stronger, it is which brand your prescription and your insurance are written for.

What dose strengths does Zepbound come in?

Zepbound comes in six once-weekly strengths from 2.5 mg up to 15 mg, with 2.5 mg used only as a starter dose to ease the body in, not as a maintenance dose. Knowing the ladder helps you understand both the titration plan and the pricing tiers.

The six strengths are 2.5, 5, 7.5, 10, 12.5, and 15 mg (Eli Lilly, LillyDirect, 2026). A clinician almost always starts at 2.5 mg once weekly for four weeks, then steps up by 2.5 mg increments every four weeks as tolerated, toward a maintenance dose. That slow climb, called titration, is what keeps the mostly digestive side effects manageable. Not everyone climbs to 15 mg; the maintenance dose is whatever balances results against tolerance, and 5 mg, 10 mg, or 15 mg are all common landing spots.

Zepbound is supplied two ways: a prefilled single-dose pen (and a multidose KwikPen) and single-dose vials. The vials matter for cost, because Lilly sells them cheaper through its direct self-pay channel, covered in the cost section. The full week-by-week titration schedule and the missed-dose logic live in the tirzepatide molecule guide, so this hub keeps it brand-level.

How much does Zepbound cost in 2026?

Zepbound's list price is roughly $1,086 a month, but most self-pay patients pay far less by buying single-dose vials through Lilly's direct channel, where the 2.5 mg starter runs about $299 and 5 mg about $399 a month. What you actually pay depends on whether you have coverage, which form you buy, and which program you use.

There are a few prices worth separating, because they get confused constantly:

  • List price (the pen): about $1,086 a month before insurance, set by Eli Lilly (Eli Lilly, LillyDirect, 2026). This is the sticker price, not what most cash-pay people pay.
  • Self-pay single-dose vials (LillyDirect): roughly $299 a month for 2.5 mg and $399 for 5 mg, with higher doses around $449, when bought directly and refilled on schedule (Eli Lilly, LillyDirect, 2026).
  • With commercial insurance plus a savings card: eligible, commercially insured patients may pay as little as about $25 a month through Lilly's savings offer (confirm current eligibility and term limits on the official savings page).

The single-dose vials are the headline cost story: by selling them at a flat self-pay price through LillyDirect, Lilly created a cheaper on-ramp than the branded pen for people without good coverage. The catch is the refill schedule. To keep the lower self-pay price, you generally have to reorder on time; let too many weeks lapse between refills and the price can step back up. The vials also take a little more handling than the prefilled pen, since you draw the dose yourself, so they trade convenience for cost.

Because these prices move and depend on refilling on time, treat them as a 2026 snapshot rather than a quote, and confirm the current figure with the pharmacy or LillyDirect before you commit. The same caution applies to the savings-card figure: the headline "as little as $25" depends on having eligible commercial insurance and on terms that Lilly can change. The tirzepatide molecule guide tracks the full pricing and access breakdown across both Zepbound and Mounjaro.

What people pay for Zepbound per month (2026)Monthly Zepbound price by route (2026)Approximate US figures. What you pay depends on coverage, form, and refilling on time.List price (pen)~$1,086Self-pay vial (5 mg)~$399Self-pay vial (2.5 mg)~$299Insured + savings card~$25Sources: Eli Lilly LillyDirect (list price and self-pay vial prices); Lilly savings offer. Figures vary; confirm before purchase.
Lilly's self-pay single-dose vials sit well below the branded pen's list price, which is the main 2026 cost story.

Is Zepbound covered by insurance or Medicare?

Coverage for Zepbound is patchy: some commercial plans cover it for weight management or sleep apnea with prior authorization, but Medicare is barred by federal law from covering any drug used purely for weight loss. Coverage hinges on your plan and the diagnosis on the prescription.

For weight management, many commercial plans either exclude Zepbound or require step therapy and prior authorization, which is the single biggest reason people end up paying cash. Step therapy means trying a cheaper option first; prior authorization means your clinician has to justify the prescription before the plan agrees to pay. Even when a plan does cover Zepbound for weight, it may cap the duration or require documented progress to keep paying. The newer sleep-apnea indication can change that math, because obstructive sleep apnea is a medical diagnosis some plans treat more favorably than obesity alone, so a Zepbound prescription written for OSA may clear hurdles that a weight-loss prescription would not. It is worth asking your clinician and your plan specifically how each indication is handled before you assume you are stuck paying full price.

Medicare is the firmer wall. By statute, Medicare cannot cover a drug used only for weight loss (KFF, 2025). Coverage for a non-weight indication such as sleep apnea is a separate question that depends on the plan. Federal officials have floated models to expand GLP-1 coverage for obesity through Medicare and Medicaid later this decade, but until any of that lands, the practical rule for Zepbound stands: rarely covered for weight alone, sometimes covered for sleep apnea, and often a cash purchase (KFF, 2025).

How do you get Zepbound?

You get Zepbound with a prescription from a licensed clinician, filled at a pharmacy or through Lilly's direct self-pay channel; the legitimate route always ends with genuine, pharmacy-dispensed product. There is a clear path and a risky shortcut.

The legitimate path looks like this:

  1. See a clinician (primary care, an obesity-medicine specialist, a sleep specialist, or a vetted telehealth provider) who confirms you are an appropriate candidate for weight management or sleep apnea.
  2. Get a prescription for branded Zepbound at the starting 2.5 mg dose.
  3. Fill it at a licensed pharmacy or through Lilly's LillyDirect self-pay service, which dispenses genuine, quality-controlled product.
  4. Sort out cost using insurance, a savings card, or the self-pay vial option before you commit to a long course.
  5. Follow the titration plan your clinician sets, stepping the dose up slowly to limit side effects.

The shortcut to avoid is buying vials labeled "research use only," "compounded," or shipped from overseas sellers. The FDA resolved the tirzepatide shortage in 2024, which removed the legal basis for mass compounding, so those products are no longer a quality-verified option and you cannot confirm what is inside. For how to evaluate any peptide's paperwork, see are peptides legal.

A bright, modern pharmacy pickup counter with a clinician's hand passing a small medication box to a patient, warm natural light, clean and professional, no readable text or logos.

What does our community usage data show?

Within the ProtocolPlus community, tirzepatide (the drug in Zepbound and Mounjaro) is the single most-tracked compound, and members typically finish a reconstituted vial in about three weeks, consistent with once-weekly use. These are usage-pattern figures from our app, labeled as community signal, not a clinical or stability claim.

In our anonymized tracking data, tirzepatide accounts for the largest share of activity: 52,400 logged doses from 8,384 tracking users, drawn from a global window of 27,272 unique trackers and 233,668 logged doses (data window September 2024 to June 2026). The median vial in our community runs about 22 days from first to last logged dose, clustering around a three-week window that mirrors weekly dosing. As with all our app data, these numbers describe how people use the compound, not how long it is chemically stable.

Tirzepatide share of community trackingTirzepatide in our community dataShare of all logged doses. ProtocolPlus app data.~22%of logged dosesTirzepatide: 52,400 dosesAll other compounds: 181,2688,384 tracking usersMedian vial: ~22 daysUsage convention, not a validated claim. Source: ProtocolPlus userbase.json, n=8,384 users.
Tirzepatide is the most-tracked compound in our community, a usage signal that mirrors Zepbound's and Mounjaro's real-world popularity.

Frequently Asked Questions

In the SURMOUNT-1 trial, adults with obesity or overweight lost an average of about 15% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at the 15 mg dose over 72 weeks, alongside diet and exercise. These are clinical-trial averages, not a guarantee for any individual, and results depend on dose, adherence, and lifestyle.

The bottom line

Zepbound is the weight-loss face of tirzepatide, Eli Lilly's once-weekly dual-hormone injection that delivered the standout SURMOUNT weight-loss numbers and, head-to-head, beat Wegovy on average weight lost. It is also the first drug ever approved for obstructive sleep apnea, which gives it a second, distinct lane that some insurers treat more favorably than weight loss. Its diabetes-branded twin, Mounjaro, is the identical molecule under a different label.

If you take away one idea, make it this: with Zepbound the molecule is the same tirzepatide you would get as Mounjaro, so the real decisions are about brand, indication, and cost. Match the brand to the approved use, weigh it against Wegovy on more than the headline percentage, confirm coverage before you start, and get the genuine product through a licensed pharmacy or LillyDirect. From here, the natural next steps are the tirzepatide molecule guide, the Zepbound vs Wegovy comparison, and the Mounjaro guide. And for anything you might consider, talk to a qualified clinician first.

Sources